Christopher Raymond
Stock Analyst at Piper Sandler
(0)
# 4027
Out of 5,270 analysts
149
Total ratings
46.39%
Success rate
-4.28%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Biomarin Pharmaceuti... | Maintains: Overweight | 122 126 | 71.39 | 76.5% | 12 | Feb 20, 2025 | |
Biogen | Reiterates: Neutral | 138 135 | 142.16 | -5.04% | 16 | Feb 18, 2025 | |
Q32 Bio | Downgrades: Neutral | 20 4 | 2.17 | 84.33% | 3 | Feb 11, 2025 | |
Ardelyx | Maintains: Neutral | 7 8 | 5.2 | 53.85% | 7 | Jan 27, 2025 | |
Blueprint Medicines | Maintains: Neutral | 109 119 | 90.28 | 31.81% | 4 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 535 533 | 488.13 | 9.19% | 8 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 1195 1013 | 687.82 | 47.28% | 7 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 135 140 | 41.87 | 234.37% | 5 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 43 30 | 1.12 | 2578.57% | 1 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 72 | 32.4 | 122.22% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 212 220 | 211.25 | 4.14% | 11 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 3 13 | 1.96 | 563.27% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 60 75 | 7.23 | 937.34% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 66 76 | 33 | 130.3% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 10 10 | 0.9 | 1011.11% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 33 | 11.35 | 190.75% | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 9 7 | 1.6 | 337.5% | 2 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 42 | 7.29 | 476.13% | 1 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 11 21 | 1.03 | 1938.83% | 5 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 621 35 | 10.02 | 244.31% | 2 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 18 23 | n/a | n/a | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 20 4 | n/a | n/a | 3 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 22 | 7.12 | 208.99% | 1 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 2 4 | 1.81 | 120.99% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 25 17 | n/a | n/a | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 26 25 | 6.67 | 274.81% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 293 288 | 309.49 | -6.94% | 11 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 41 | 33.53 | 22.28% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 3 1 | n/a | n/a | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 6 2 | n/a | n/a | 3 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 28 | 48.8 | -42.62% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 40 12 | n/a | n/a | 2 | May 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 56 28 | n/a | n/a | 4 | May 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 146 180 | n/a | n/a | 2 | Sep 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 40 | 71.68 | -44.2% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 90 | 5.29 | 1601.32% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | n/a | n/a | n/a | 3 | Oct 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 60 35 | n/a | n/a | 1 | Aug 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 20 | n/a | n/a | 1 | Apr 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 96 | 1.88 | 5006.38% | 2 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 170 | n/a | n/a | 1 | Oct 23, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Neutral | 133 | n/a | n/a | 2 | Oct 23, 2017 |